Join The Discussion

 

Group buys former Armour meatpacking site in Stockyards

The 16.8-acre site of the historic, former Armour meatpacking plant in Fort Worth’s Stockyards has changed hands, and its new owners aren’t saying anything about their plans. Chesapeake Land Development Co., which bought the site

read more >

Hulen Pointe Shopping Center sold

Hulen Pointe Shopping Center, located in southwest Fort Worth on South Hulen Street one mile south of Hulen Mall, has been purchased by Addison-based Bo Avery with TriMarsh Properties for an undisclosed price.

read more >

Dallas-Fort Worth in top five commercial real estate markets in 2015

According to the Emerging Trends in Real Estate 2015 report, just co-published by PwC US and the Urban Land Institute (ULI), Dallas-Fort Worth ranks No. 5, with two other Texas cities, Houston and Austin ranking at No. 1 and 2 respectively. San Francisco ranks No. 3 and Denver No. 4.

read more >

Social House Fort Worth plans to open mid-November

Social House has leased 5,045 square feet at 2801-2873 W Seventh St. in Fort Worth, according to Xceligent Inc.

read more >

Fort Worth temporarily stops issuing new home permits in TCU area

The moratorium will give a committee and the City Council time to review a proposed overlay that will pare the number of permissible unrelated adults living in the same house.

read more >

Galderma now shipping new topical rosacea treatment

Galderma headquarters in Fort Worth. 

Photo courtesy of Galderma

By Carolyn Poirot 

Fort Worth Business Press Health Correspondent 

cpoirot@bizpress.net

A local company is now selling what is said to be the first-ever topical gel created specifically to combat the facial erythema (redness) of rosacea.
The U.S. Food and Drug Administration approved Mirvaso topical gel, developed by Galderma Laboratories L.P. in late August, and the product reached most pharmacies around the country earlier this month, a company spokesman said Thursday. The product is available by prescription. 


“This milestone exemplifies Galderma’s continued, two-decade-long commitment to R&D to address the unmet needs of rosacea patients and clinicians,” said Francois Fournier, president of North American Operations for Galderma Laboratories, headquartered in Fort Worth.
“Mirvaso Gel marks a turning point in rosacea treatment. Mirvaso is going to fill a great vacuum in the armamentarium of products to address the daily stress and anxiety caused by the persistent facial redness of rosacea – providing patients with an effective topical therapy,” Fournier said.


An estimated 16 million Americans are affected by rosacea, a chronic inflammatory and vascular disorder characterized by redness, visible blood vessels, bumps and blemishes on the forehead, nose and cheeks, according to the National Rosacea Society.
Dealing with erythema – the most common symptom of rosacea – every day can be embarrassing and cause anxiety and frustration, a survey from the Rosacea Society found. Some 76 percent of people with the disorder say rosacea’s effect on their facial appearance lowered their self-confidence and self-esteem.
Although the cause of rosacea is unknown, common triggers include sun exposure, emotional stress, hot or cold weather, heavy exercise, alcohol, spicy foods, heated beverages, humidity and certain skin-care products, the Rosacea Society says on its website.
Patients should use the medication as directed by their physicians, but Mirvaso Gel can be used daily to reduce the persistent redness of rosacea, a company spokesman said. Pea-size amounts are applied to each of the five regions of the face: the forehead, chin, nose and each cheek.


More than 45 million people worldwide have symptoms of the disorder, the Rosacea Research & Development Institute says.
Among the most famous rosacea sufferers is former President Bill Clinton, whose diagnosis was reported in the New York Times. Others have included comedian W.C. Fields, Princess Diana, financier J.P. Morgan and the Dutch painter Rembrant, according to the Rosacea Society.
Interest in the new prescription gel that works within 30 minutes of application and lasts up to 12 hours, has been high, and Galderma has been actively meeting with managed care companies working to ensure that patients have access to this first-in-class therapeutic option, a company spokesman said.


Galderma is committed to research and development of new products in dermatology, and several other new medical solutions addressing major dermatological needs will be launched in the next years, Fournier said.
“An innovation such as Mirvaso Gel is a strong example of Galderma’s continuous commitment to investing in skin research and delivering innovative medical solutions to address unmet dermatological needs,” he said. “Galderma has chosen to invest each year approximately 20 percent of its global revenues in research and development.”
 

< back

Email   email
hide
Ebola
How worried are you about Ebola spreading?